Based on the aforementioned findings, we hypothesized that miR-26a delivered from GSCs into MVECs via exosomes could potentially provide an effective therapeutic strategy for glioma by controlling PTEN and regulating the PI3K-Akt pathway. The gene discussed is PTEN; the disease is central nervous system cancer.